Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Author:

Hughes Timothy P.1,Mauro Michael J.1,Cortes Jorge E.1,Minami Hironobu1,Rea Delphine1,DeAngelo Daniel J.1,Breccia Massimo1,Goh Yeow-Tee1,Talpaz Moshe1,Hochhaus Andreas1,le Coutre Philipp1,Ottmann Oliver1,Heinrich Michael C.1,Steegmann Juan L.1,Deininger Michael W.N.1,Janssen Jeroen J.W.M.1,Mahon Francois-Xavier1,Minami Yosuke1,Yeung David1,Ross David M.1,Tallman Martin S.1,Park Jae H.1,Druker Brian J.1,Hynds David1,Duan Yuyan1,Meille Christophe1,Hourcade-Potelleret Florence1,Vanasse K. Gary1,Lang Fabian1,Kim Dong-Wook1

Affiliation:

1. From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) — both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) —...

Funder

Novartis Pharmaceuticals Corporation

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3